Joseph Gilliam Sells 10,498 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 10,498 shares of the company’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $127.68, for a total value of $1,340,384.64. Following the completion of the sale, the chief operating officer owned 92,366 shares of the company’s stock, valued at $11,793,290.88. This represents a 10.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Glaukos Stock Performance

Shares of Glaukos stock opened at $118.75 on Wednesday. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The stock’s fifty day moving average price is $111.79 and its 200-day moving average price is $96.40. The firm has a market cap of $6.82 billion, a P/E ratio of -77.11 and a beta of 0.67. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $161.78.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The company had revenue of $133.54 million for the quarter, compared to analysts’ expectations of $122.55 million. During the same period in the prior year, the business earned ($0.28) EPS. The firm’s quarterly revenue was up 38.1% on a year-over-year basis. On average, equities research analysts expect that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Institutional Trading of Glaukos

A number of institutional investors have recently bought and sold shares of the stock. Riverbridge Partners LLC boosted its position in Glaukos by 41.0% in the 3rd quarter. Riverbridge Partners LLC now owns 569,644 shares of the medical instruments supplier’s stock worth $46,454,000 after purchasing an additional 165,673 shares in the last quarter. Holocene Advisors LP lifted its stake in shares of Glaukos by 40.1% in the 2nd quarter. Holocene Advisors LP now owns 1,045,886 shares of the medical instruments supplier’s stock valued at $108,030,000 after purchasing an additional 299,118 shares during the period. Baird Financial Group Inc. boosted its holdings in Glaukos by 17.7% during the second quarter. Baird Financial Group Inc. now owns 63,379 shares of the medical instruments supplier’s stock worth $6,546,000 after buying an additional 9,545 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in Glaukos by 4.2% during the second quarter. State of New Jersey Common Pension Fund D now owns 19,905 shares of the medical instruments supplier’s stock valued at $2,056,000 after buying an additional 800 shares during the period. Finally, Divisadero Street Capital Management LP purchased a new position in Glaukos in the second quarter valued at $10,514,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price objective on shares of Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Truist Financial boosted their price target on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research note on Thursday, January 22nd. JPMorgan Chase & Co. lifted their target price on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Finally, Citigroup increased their price target on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $131.38.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.